• Happy Holidays from AcceGen! Orders placed during Dec 22–Jan 2 will be processed and shipped after operations resume. Please plan ahead.

Tumor Cell Lines

NEC8

  • For research use only

Cat No.

ABL-TC0464

Product Type

Human Germ Cell Cancer Cell Lines

Species

Human

Growth Conditions

37 ℃, 5% CO2

Source Organ

Testis

Product Code

NEC-8

NEC8 cells grow adherently and express cancer stem cell genes, showing strong tumorigenic potential and trophoblastic differentiation abilities.

Product Image

Description

Brightfield micrograph of NEC8, showing adherent growth, 4X magnification.
NEC8 is a human embryonal carcinoma cell line derived from a testicular germ cell tumor of a 24-year-old East Asian male patient. This epithelial-like cell line grows adherently in vitro and exhibits high expression of globo-series glycosphingolipids (Gb4 and Gb3), along with cancer stem cell-associated genes such as GADD45β. The cytoplasm of NEC8 cells is characterized by a high abundance of glycogen granules, leading to a strong periodic acid-Schiff (PAS) reaction. Although androgen receptor (AR) expression is relatively low compared to seminoma-derived cells, NEC8 demonstrates tumorigenic potential and primarily consist primarily of embryonal carcinoma cells with the potential for trophoblastic differentiation.
Product Code

NEC-8

Species

Human

Cat.No

ABL-TC0464

Product Category Tumor Cell Lines
Size/Quantity

1 vial

Shipping Info

Dry Ice

Growth Conditions

37 ℃, 5% CO2

Source Organ

Testis

Biosafety Level

1

Storage

Liquid Nitrogen

Product Type

Human Germ Cell Cancer Cell Lines

Application

  • NEC8 plays a crucial role in testicular cancer research, particularly for studying pathogenesis and progression of embryonal carcinoma, a highly malignant subtype of non-seminomatous germ cell tumors. It is frequently used to investigate the molecular mechanisms underlying chemoresistance, aiding in identifying factors responsible for chemotherapeutic resistance in testicular germ cell tumors, offering insights into potential strategies to overcome this resistance. Moreover, NEC8 provides a platform the discovery and evaluation of novel immunotherapy targets, paving the way for the development of innovative, targeted treatment approaches to combat these aggressive malignancies.

Citation

When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).

Inquiring NEC8

We know how valuable your research is to you, but are you wondering what you can expect to pay for quick accurate results every time? Fill out a request in the form below and we’ll get back to you within 24 hours with a quote.
High Viability
To succeed in cell culture
Precision and Reliability
To support a consistent result
Customization Options
Tailed to your research

Tags

AcceGen Scroll Top Button